| Date Filed | Type | Description |
| 10/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/10/2023 |
8-K
| Quarterly results |
| 10/10/2023 |
SC 13G/A
| FIL Ltd reports a 8.4% stake in TERNS PHARMACEUTICALS INC |
| 10/04/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 07/28/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 05/15/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners III, L.P. reports a 7.7% stake in Terns Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Fairmount Funds Management LLC reports a 9.9% stake in Terns Pharmaceuticals, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/13/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 02/10/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 14.9% stake in TERNS PHARMACEUTICALS INC |
| 02/09/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/05/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET, the first trial assessing THR-β agonist as monotherapy and in combination with FXR agonist for NASH Cash and cash equivalents, together with the $112 million from proceeds raised in December 2022, expected to provide runway into 2026 FOSTER CITY, Calif., Jan. 5, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non..." |
|
| 01/03/2023 |
SC 13G
| SUVRETTA CAPITAL MANAGEMENT, LLC reports a 7% stake in Terns Pharmaceuticals, Inc. |
| 12/29/2022 |
SC 13G/A
| LAV Biosciences Fund V, L.P. reports a 6.2% stake in Terns Pharmaceuticals, Inc. |
|